NFL Biosciences: Activities & 2021 Annual Results
Implementation of the Phase II/III clinical study of the drug candidate NFL-101 for smoking cessation: first patients recruited and increase in recruitment capacity
Strengthening of the organization and establishment of a manufacturing partnership for active ingredients
Extension of intellectual property with the registration of an NFL Biosciences patent in the United States
Co-development agreement for drug candidate NFL 301 to reduce alcohol consumption
NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company that develops botanical drugs for the treatment of addictions and addictions, presents its 2021 annual results approved by the Board of Directors on March 24, 2022 and reviews its progress following its listing on Euronext Growth Paris in early July 2021.